Advice
Following a full submission
Imiquimod 5% (Aldara) is accepted for restricted use within NHS Scotland for the topical treatment of small superficial Basal Cell Carcinoma in adult patients in whom standard treatment with surgery or cryotherapy is contraindicated. Its use should be supervised by specialists in dermatology.
At 12 weeks post treatment the composite clearance rates in the randomised controlled trials were between 73-77% and initial clearance rates in the open label studies were between 90- 94%. There is only limited follow-up data beyond 12 months.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- Imiquimod 5% cream (Aldara®)
- SMC ID:
- 167/05
- Indication:
- Topical treatment of small superficial Basal Cell Carcinoma
- Pharmaceutical company
- 3M Healthcare Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 May 2005